Compare DTSS & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DTSS | MBAI |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7M | 8.8M |
| IPO Year | 2026 | 2014 |
| Metric | DTSS | MBAI |
|---|---|---|
| Price | $0.70 | $6.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 422.6K | 69.4K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.58 | $0.95 |
| 52 Week High | $2.50 | $10.21 |
| Indicator | DTSS | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | 41.78 | 64.47 |
| Support Level | $0.61 | $1.19 |
| Resistance Level | $0.84 | $10.21 |
| Average True Range (ATR) | 0.05 | 0.49 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 34.49 | 60.48 |
Datasea Intelligent Technology Ltd, formerly known as Datasea Inc, is a technology company that operates in two main segments. The first segment, Acoustic High-Tech, focuses on developing and applying acoustic technologies, such as ultrasound, infrasound, and mechanical wave effects, for applications like ultrasonic sterilization, neuro-regulation, acupoint stimulation, and environmental purification. The second segment, AI Multimodal Digitalization, integrates artificial intelligence with 5G networks and big data processing to create a proprietary multimodal data platform that combines text, voice, image, and video for real-time intelligent analysis and generation. The company generates all of its revenue from the People's Republic of China (PRC).
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.